Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Acute glaucoma combined with herpes zoster ophthalmicus (HZO) in a patient with anterior chamber intraocular lens

Poster Details

First Author: T.Lalias GREECE

Co Author(s):    E. Kanonidou   G. Karagiannidis-Stampoulis                 

Abstract Details

Purpose:

To present a case of acute glaucoma in a patient with AC-IOL combined with HZO and lessons learned.

Setting:

Department of Ophthalmology, Hippokrateion General Hospital of Thessaloniki, Thessaloniki, Greece

Methods:

A 85-year-old patient presented due to acute periorbital pain and reduction of visual acuity in the left eye (LE).He was a primary open angle glaucoma patient (POAG) treated with combination of dorzolamide/timolol eye drops bd and latanoprost eye drops od in both eyes.He also had an AC-IOL in LE. Best corrected visual acuity (BCVA) was 9/10 RE and hand movement LE. Intraocular pressure (IOP) was 18mmHg RE and 62mmHg LE with corneal edema and fixed dilated pupil. Regarding his medical history he had diabetes type II, hypertention and cicatricising pemphigoid for which he was on chronic treatment with systemic methylprednisolone.

Results:

The patient was diagnosed with acute glaucoma LE and commenced treatment with tb acetazolamide 250mg and iv mannitol. Also brimonidine eye drops bd were commenced in LE. IOP was reduced to19mmHg LE and BCVA improved to 3/10, however the periobital pain persisted. One day later cutaneus macular rash appeared on the left, characteristicof HZO. Treatment was started with tb aciclovir 800mg x5 and the patient was referred to the Dermatology department.

Conclusions:

AC-IOL implant can cause acute glaucoma possibly in relation to uveitis-glaucoma-hyphema (UGH) syndrome. Sometimes it can be accompanied with other conditions with misleading symptoms, therefore thorough examination is required.

Financial Disclosure:

None

Back to Poster listing